|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.54 USD | -3.51% |
|
+20.70% | +193.73% |
| May. 07 | Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating | MT |
| May. 06 | Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M | MT |
Stoke Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 5.15 million compared to USD 3 million a year ago. Net loss was USD 22.55 million compared to USD 24.65 million a year ago.
Basic loss per share from continuing operations was USD 0.53 compared to USD 0.66 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +193.73% | 839M | |
| +40.23% | 54.04B | |
| +43.57% | 41.96B | |
| -1.17% | 41.92B | |
| -7.59% | 28.35B | |
| +12.55% | 26.35B | |
| -22.17% | 19B | |
| +7.85% | 13B | |
| +28.29% | 12.28B | |
| +25.17% | 12.19B |
STOKE THERAPEUTICS, INC. 